Form 8-K - Current report:
SEC Accession No. 0000950170-25-066947
Filing Date
2025-05-08
Accepted
2025-05-08 16:10:08
Documents
13
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20250508.htm   iXBRL 8-K 41256
2 EX-99.1 crdf-ex99_1.htm EX-99.1 185720
3 GRAPHIC img186708884_0.jpg GRAPHIC 14426
  Complete submission text file 0000950170-25-066947.txt   368181

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crdf-20250508.xsd EX-101.SCH 23903
15 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20250508_htm.xml XML 4500
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 25926128
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)